HERV-W and *Mycobacterium avium* subspecies *paratuberculosis* Are at Play in Pediatric Patients at Onset of Type 1 Diabetes

Marta Noli 1, Gianfranco Meloni 2, Pietro Manca 3, Davide Cossu 1, Mario Palermo 4 and Leonardo A. Sechi 1,5,6,*

**Abstract:** The etiology of T1D remains unknown, although a variety of etiological agents have been proposed as potential candidates to trigger autoimmunity in susceptible individuals. Emerging evidence has indicated that endogenous human retrovirus (HERV) may play a role in the disease etiopathogenesis; although several epigenetic mechanisms keep most HERVs silenced, environmental stimuli such as infections may contribute to the transcriptional reactivation of HERV-W and thus promote pathological conditions. Previous studies have indicated that also *Mycobacterium avium* subspecies *paratuberculosis* (MAP) could be a potential risk factor for T1D, particularly in the Sardinian population. In the present study, the humoral response against HERV-W envelope and MAP-derived peptides was analyzed to investigate their potential role in T1D etiopathogenesis, in a Sardinian population at T1D onset (*n* = 26), T1D patients and healthy controls. For the first time, a high serum-prevalence of anti-Map and anti-HERV-W Abs was observed in pediatric patients at onset of T1D compared to T1D patients and healthy controls. Our results support the hypothesis that external infections and internal reactivations are involved in the etiology of T1D, and that HERV-W activation may be induced by infectious agents such as MAP.

**Keywords:** HERV-W; *Mycobacterium paratuberculosis*; antibodies; molecular mimicry; proinsulin; children T1D onset; peptides

1. **Introduction**

Type 1 diabetes (T1D) is an autoimmune disorder afflicting millions of people around the world, characterized by T cell infiltration within pancreatic islets and marked by the production of autoantibodies to the beta-cell [1]. The destruction of 90% of beta cells is related to the onset of the clinical symptoms [2]. The major genetic determinant of T1D are polymorphisms within the HLA region [3], although over 60 non-HLA loci T1D susceptibility loci have been identified [4]. However, the genetic drift alone cannot explain the increase in the incidence of T1D, and environmental factors are thought to play a critical role in triggering islet autoimmunity [5,6]. A variety of studies suggested that the environmental agents trigger disease development in genetically susceptible subjects [7,8]. The loss of self-tolerance and the development of the immune response can be
a consequence of the mechanism of cross-reactivity associated with the molecular mimicry provoked by infectious factor [9]. A number of factors, including diet, intestinal dysbiosis, viral infections such as enteroviruses (coxsackieviruses, rotaviruses, cytomegalovirus, parvovirus), have been explored as potential risk factor for the disease progression, but no causal relationship has been established [8].

Previous studies have indicated that Mycobacterium avium subspecies paratuberculosis (MAP) could be a potential risk factor for T1D [10,11]. MAP is the etiological agent of Johne’s disease, a chronic and inflammatory bowel disease that affects ruminants [12]. The primary route of MAP transmission is oral-fecal through ingestion of contaminated milk, water or the environment caused by infected animals [13–15].

MAP is able to invade the intestinal mucosa by interacting with enterocytes [16]. MAP is endemic in the ruminant population of Sardinian Island, an area with one of the highest incidences of T1D in the world [17] and numerous clinical studies have linked MAP to T1D in the Sardinian population [10]. We previously identified different MAP peptides based on the sequence homologies present with human proteins including zinc transporter protein 8 (ZnT8) and with proinsulin (PI) and use them in ELISA [10].

Emerging evidence has also indicated that human endogenous retrovirus (HERV) may play a role in T1D etiopathogenesis [18,19], and it has been reported to function also as a superantigen due to the ability to induce a strong T cell responses [20].

Part of the human genome, about 8%, is composed of HERV, which until recently were considered junk DNA. The integrations of the provirus genome into the DNA of germinal cells are the remnants of infections that occurred over several million years; however, numerous nonsense mutations have rendered them defective [21]. The envelope proteins of HERV-W (HERV-Wenv) has been detected in serum, in peripheral blood mononuclear cells and within the pancreas of patients with T1D [18–20], also, in an in vitro study in transgenic mice, HERV-Wenv repressed internal insulin secretion [22,23]. The monoclonal antibody GNbAC1, has been developed to neutralize the effects of HERV-Wenv, and is currently in phase IIA clinical trials as a possible HERV-based therapeutic approach in T1D [24]. Interestingly, not all HERVs remain silenced, and they can be reactivated under certain pathological condition such as infection [24]. The aim of this study was to investigate the role of MAP and HERV in a Sardinian pediatric population with T1D, analyzing the humoral response against homologues peptides derived from both pathogens. Collectively, data obtained from this study support the involvement of MAP and to HERV-Wenv in the loss of immune tolerance that leads to autoimmunity in T1D. Furthermore, a positive correlation between anti-MAP and anti-HERV-Wenv antibodies observed, suggested a potential relationship between MAP seropositivity and reactivation of HERV.

2. Materials and Methods

2.1. Patients

A total of 45 children with T1D pediatric and young patients (median age 12.6, \(n = 18\) females and \(n = 27\) males mean years with T1D = 6) and 26 patients with onset of T1D (median age 7.8, \(n = 7\) females and \(n = 19\) males) recruited at the time of diagnosis and blood sampling was performed before starting with insulin therapy, were enrolled in this retrospective study. The inclusion criteria were diagnosis of T1D upon manifestation of the clinical symptoms such as severe hyperglycemia e/o ketoacidosis, testing for the presence of classical islet autoantibodies, as well as levels of glycated hemoglobin, according to the American Diabetes Association criteria [25]. Clinical data of T1D patients are available in Supplementary Table S1. Forty-five healthy and age-matched (median age 11.8 years, 29 females, 16 males) volunteers without autoimmune diseases and inflammatory episodes in the last 2 months served as controls. Patients were recruited at the Pediatrics department of the AOU of Sassari and Department of Experimental and Clinical Medicine of the University of Sassari, while controls samples were obtained from the Department of Endocrinology of the University Hospital (AOU) of Sassari and written informed consent.
from a parent or legal tutor was obtained for all study participants. All methods were performed in accordance with regional and national regulations.

2.2. Blood Samples

Five to eight mL of peripheral blood was taken from each individual in EDTA tubes which was processed within 12 h of collection. Plasma was obtained using Ficoll-Paque® (Cynthia Europe Milano, Italy) according to the protocol. Plasma rates was immediately transferred into a clean polypropylene tube and apportioned into 0.5 mL aliquots and transported at –20 °C for short-term storage (<6 months) and −80 °C for long-term storage (>6 months).

2.3. Peptides

Peptides showed in Table 1: MAP 3865c 125–133 (MIAVALAGL), MAP 3865c 133–141 (LAANFVVAL), MAP 2404c 70–80 (RGFVVLVTRRDVTDV) and MAP 1,4-α-gbp 157–173 (GTVELGGLAHFPQPL), HERV-Wenv 93–108 (NPSCPGLGVTVCWTY), HERV-Wenv 129–143 (VKEVISQLTRVRHG), HERV-Wenv 248–262 (NSQCIRWVTPTQIV) were synthesized at ≥95% purity (LifeTein, South Plainfield, NJ, USA) assessed by HPLC. The peptides were resuspended in 10 mM of dimethyl sulfoxide (DMSO) and kept in single-use aliquots at −80 °C.

Table 1. Epitopes identified in MAP and HERV-Wenv.

| Peptides     | Position | Sequence          |
|--------------|----------|-------------------|
| MAP 3865c    | aa 125–133 | MIAVALAGL        |
| MAP 3865c    | aa 133–141 | LAANFVVAL        |
| MAP 2404c    | aa 70–80    | RGFVVLVTRRDVTDV  |
| MAP 1,4-α-gbp| aa 157–173  | GTVELGGLAHFPQPL  |
| HERV-Wenv    | aa 93–108   | NPSCPGLGVTVCWTY  |
| HERV-Wenv    | aa 129–143  | VKEVISQLTRVRHG   |
| HERV-Wenv    | aa 248–262  | NSQCIRWVTPTQIV   |

aa: Aminoacids.

2.4. Enzyme-Linked Immunosorbent Assay (ELISA)

Ninety-six-well plates (Nunc-Immuno™ Plates, Maxi Sorp, Nalgen Nunc International, Rochester, NY, USA) were coated overnight at 4 °C with 10 µg/mL of each peptide in a solution 0.05 M of carbonate-bicarbonate, pH 9.5 (Sigma-Aldrich, St. Louis, MO, USA). Plates were washed two times with 0.1% Tween-20 (in TBS) and blocked with 5% skimmed dried milk in PBS for 1 h at room temperature (25 °C). Plasma samples (1:1000 dilution) were added and incubated for 2 h at room temperature. Secondary antibody was alkaline phosphatase-conjugated goat anti-human immunoglobulin G polyclonal Ab (1:1000; Merk Life Science S.r.l., Milano, Italy). Plates were washed between each incubation. Alkaline phosphatase was detected with para nitrophenyl phosphate (Merk Life Science S.r.l., Milano, Italy). Absorbance was read at 405 nm on a plate reader (SpectraMax Plus 384, Molecular Devices, Sunnyvale, CA, USA). All incubation volumes were 100 µL/well.

Each sample was run in duplicated, and normalization was performed with a positive control (absorbance reactivity set at 1.0 arbitrary units) included in each assay. Background activity was calculated as the mean signal of an immobilized peptide with secondary Ab alone.

2.5. Statistical Analysis

GraphPad Prism 9.0 software (GraphPad Software, San Diego, CA, USA) was used for calculating the sensitivity and specificity, false negative and false positive values. Mann–Whitney test were used to analyze non-parametric data. For evaluation of diagnostic values of Ab, receiver operating characteristic curve (ROC) and area under the curve (AUC) was established. Fisher’s exact test and Spearman’s were used for comparison and correlation between MAP and HERV-Wenv peptides, respectively; \( p < 0.05 \) was considered statistically significant.
3. Results

3.1. Seroreactivity against MAP Antigens

Significant differences were detected between the patient’s groups and the control group in terms of positivity and mean levels of anti-MAP Abs. The positivity and mean levels of anti-MAP 3865c_125–133 Abs were significantly more frequent in T1D patients (28.89%, 13 out of 45) than in the healthy controls (HCs) (4.44%, 2 out of 45) (cut-off value of 0.41; AUC = 0.69; p < 0.0016, Figure 1A), and were significantly higher in patients with onset of T1D (65.38%, 18 out of 26) than in HCs (2.86%, 1 out of 35) (cut-off value 0.42; AUC = 0.84; p < 0.0001, Figure 1B). Anti-MAP 3865c_133–141 Abs were detected in patients with onset of T1D (73.08%, 19 out of 26) and in HCs (5.71%, 2 out of 35) (cut-off value 0.38; AUC = 0.80; p < 0.0001, Figure 1D); anti-MAP 1,4-α-gbp_157–173 Abs were detected in patients with onset of T1D (57.69%, 15 out of 26) and HCs (8.57%, 3 out of 35) (cut-off value 0.16; AUC = 0.75; p = 0.006, Figure 1F); anti-MAP 2404c_70–80 were detected in patients with onset of T1D (61.54%, 16 out of 26) and HCs (8.57%, 3 out of 35) (cut-off value 0.39; AUC = 0.78; p < 0.0001, Figure 1H). No significant differences were detected between T1D patients and HCs concerning the antibody response against MAP 3865c_133–141 (Figure 1C), MAP 1,4-α-gbp_157–173 (Figure 1E), MAP 2404c_70–80 (Figure 1G).

3.2. Seroreactivity against HERV-W Antigen

Concerning HERV-W peptides, significant differences in Ab distribution were also detected between the patient groups and the control group. Anti-HERV-Wenv_93–108 Abs were detected in T1D patients (31.11%, 14 out of 45) and in HCs (8.89%, 4 out of 45) (cut-off value of 0.36; AUC = 0.67; p = 0.0038, Figure 2A); in patients with onset of T1D (69.23%, 18 out of 26) and in HCs (8.57%, 3 out of 35) (cut-off value 0.36; AUC = 0.89; p < 0.0001, Figure 2B); Anti-HERV-Wenv_129–143 Abs were detected in T1D patients (44.44%, 20 out of 45) and in HCs (8.89%, 4 out of 45) (cut-off value of 0.3630; AUC = 0.68; p = 0.0019, Figure 2C); in patients with onset of T1D (69.23%, 18 out of 26) and in HCs (5.71%, 2 out of 35) (cut-off value 0.39; AUC = 0.78; p < 0.0001, Figure 2D).

Anti-HERV-Wenv_248–262 Abs were detected in T1D patients (44.44%, 20 out of 45) and in HCs (6.67%, 3 out of 45) (cut-off value of 0.24; AUC = 0.73; p < 0.0001, Figure 2E); in patients with onset of T1D (88.46%, 23 out of 26) and in HCs (8.57%, 3 out of 35) (cut-off value 0.24; AUC = 0.95; p < 0.0001, Figure 2F).
Figure 1. Prevalence of Abs against MAP antigens in Sardinian T1D children. Plasma samples from T1D patients, HCs and patients at T1D onset were tested against MAP 3865c\textsuperscript{125–133} (A,B), MAP3865c\textsuperscript{133–141} (C,D), MAP 1,4-α-gbp\textsuperscript{157–173} (E,F) and MAP 2404c\textsuperscript{70–80} (G,H) peptides. The dotted lines represent positivity thresholds calculated by ROC analysis; Mann–Whitney \(p\)-value and the percentage of positive patients evaluated by Fisher’s exact test are indicated in the upper part of each graph.
Figure 2. Prevalence of Abs against HERV-Wenv antigens in Sardinian T1D children. Plasma samples from T1D patients, HCs and patients at onset were tested against HERV-Wenv 93–108 (A,B), HERV-Wenv 129–144 (C,D) and HERV-Wenv 248–262 (E,F) peptides. The dotted lines represent positivity thresholds calculated by ROC analysis; Mann–Whitney p-value and the percentage of positive patients evaluated by Fisher’s exact test are indicated in the upper part of each graph.
3.3. Analysis of Correlation between Anti-MAP and Anti-HERVenv Antibody Titers

The correlation analyses in Table 2 showed a positive correlation between the antibody response against MAP epitopes and HERV-W peptides in the patients with onset of T1D. Moderate correlations on the basis of their r value are explained below: high correlation (0.7 to 0.89), moderate correlation (0.5 to 0.69), low correlation (0.3 to 0.49), little if any correlation (0.00 to 0.29) [26]. A moderate correlation was found between MAP 3865c 125–133 with HERV-Wenv 93–108 (r = 0.53, p = 0.005, Figure 3A), between MAP 3865c 125–133 and HERV-Wenv 129–143 (r = 0.51, p = 0.007, Figure 3B), and between MAP 3865c 125–133 and HERV-Wenv 248–262 (r = 0.52, p = 0.006, Figure 3C).

Table 2. Relationship between HERV-Wenv antigens and MAP-derived epitopes expressed as r. Values were obtained based on all available samples for single populations. Values were obtained based on all samples at the onset of T1D.

| MAP Antigen | HERV-Wenv 93–108 | HERV-Wenv 129–143 | HERV-Wenv 248–262 |
|-------------|------------------|------------------|------------------|
| MAP 3865c 125–133 | r = 0.5313 | r = 0.5140 | r = 0.5239 |
| | p = 0.0052 | p = 0.0072 | p = 0.0060 |
| MAP 2404c 70–80 | r = 0.7030 | r = 0.5377 | r = 0.5795 |
| | p < 0.0001 | p = 0.0046 | p = 0.0019 |
| MAP 1,4-α-gbp 157–173 | r = 0.4261 | r = 0.5852 | r = 0.4439 |
| | p = 0.0299 | p = 0.0017 | p = 0.0213 |
| MAP 3865c 133–141 | r = 0.2978 | r = 0.3759 | r = 0.4190 |
| | p ns | p ns | p = 0.0311 |

A high correlation was found between MAP 2404c 70–80 and HERV-Wenv 93–108 (r = 0.70, p < 0.0001, Figure 3D), moderate correlations between MAP 2404c 70–80 and HERV-Wenv 129–143 (r = 0.54, p = 0.005, Figure 3E), and between MAP 2404c 70–80 and HERV-Wenv 248–262 (r = 0.58, p = 0.02, Figure 3F).

A low correlation was observed between MAP 1,4-α-gbp 157–173 and HERV-Wenv 93–108 (r = 0.43, p = 0.03, Figure 3G), and between MAP 1,4-α-gbp 157–173 and HERV-Wenv 248–262 (r = 0.44, p = 0.002, Figure 3I), while a moderate correlation between MAP 2404c 70–80 and HERV-Wenv 129–143 (r = 0.58, p = 0.002, Figure 3H).

Finally, a low correlation was found between MAP 3865c 133–141 and HERV-Wenv 248–262 (r = 0.23, p = 0.03, Figure 3N), whereas no significant correlation was found between MAP 3865c 133–141 and HERV-Wenv 93–108 as well as between MAP 3865c 133–141 and HERV-Wenv 129–143 (Figure 3L,M).
4. Discussion

The incidence of type 1 diabetes in children has increased worldwide, and it is therefore important to find markers to enable early diagnosis and new treatments. Despite intensive research, the etiology of T1D remains unknown, and a multiplicity of etiological agents has been proposed as potential candidates to triggers autoimmunity in susceptible individuals with T1D [27].

The present study analyzed the potential involvement of MAP and HER-W as contributor factors in T1D etiopathogenesis, based on previous reports. Indeed, in recent studies a direct correlation between anti-MAP Abs and anti-HERV-Wenv has been observed in a cohort of patient with T1D [28].

This study demonstrates for the first time a high seroprevalence of anti-Map and anti-HERV-W Abs in pediatric patients with T1D from Sardinia. Our results support the

Figure 3. Scatter plot expressing correlation between MAP and HERV-Wenv derived peptides in a pediatric population with T1D at onset. The graphs show the correlation among MAP 3865c 125–133 and HERV-Wenv 93–108 (A); HERV-Wenv 129–143 (B); HERV-Wenv 248–262 (C); Correlation among MAP 2404c 70–80 and HERV-Wenv 93–108 (D); HERV-Wenv 129–143 (E); HERV-Wenv 248–262 (F); Correlations among MAP 1,4-α-gbp 157–173 with HERV-Wenv 93–108 (G); with HERV-Wenv 129–143 (H); HERV-Wenv 248–262 (I). Finally, correlation among MAP 3865c 133–141 with HERV-Wenv 93–108 is shown in (L); HERV-Wenv 129–143 (M); HERV-Wenv 248–262 (N) in T1D onset patients.
hypothesis that both pathogens are linked to T1D etiology and also that HERV-W activation can be induced by certain infectious agent such as MAP. To note, a possible connection between MAP and HERV-W was also showed in multiple sclerosis (MS) where it was detected a partial decrease of anti-MAP Abs and anti-HERV-Wenv in the serum of patients following treatment with natalizumab [29].

These differences may be the first step in suggesting MAP infection as a plausible circumstance capable of inducing the expression of HERV-W antigens which in turn lead to immune imbalance.

The significant results we have obtained are in line with this hypothesis, given the high reactivity expressed in patients at the onset for all peptide fragments evaluated of MAP and HERV-Wenv compared to a healthy population of corresponding age and geographical background but also compared to the population with diabetes developed for years. Interestingly, in young people receiving insulin therapy, we observed a lower antibody titer for HERV-Wenv than young people of the same age at the start of the disease. It was seen that in MAP infection Th17-derived cytokine genes were down-regulated, these play an important role in the early phase of mycobacterial infection [30], in particular IL-26, which induces immune cell initiation and direct pathogen killing [31] and IL-17F, which provides protective immunity against intracellular pathogens through modulation of the Th1 response and neutrophil recruitment [32,33].

MAP also influences the expression of interferon regulatory genes, with reduced expression of IRF4 inducing an under-regulation of the Th1 immune response, thus enhancing the persistent survival of MAP [34], and an over-regulation of IRF5 and IRF7 that may result in inhibition of T-cell proliferation through tryptophan depletion mediated by indoleamine 2,3-dioxygenase that subsequently leads to an immunosuppressive state [35].

Several factors may contribute to the transcriptional reactivation of HERV-W and may promote pathological conditions [36], some environmental stimuli such as infection immune factors and oxidative stress seems to contribute by hindering the binding of methyl groups transferred by DNA methyltransferases and enhancing gene expression following inhibition of histone deacetylases through interaction with specific binding sites in HERV promoter regions [37].

Adhesion of MAP to the mucosa lining the small intestine and subsequent uptake by M-cells and enterocytes may play a role in triggering antibody production [16] another contribution of MAP in inducing latent infection in humans could result from molecular mimicry with homologous epitopes such as ZnT8 and PI, leading to autoimmune responses [38,39].

In addition, oxidative processes have been demonstrated in patients with Crohn’s disease and in MAP-infected cattle, where an increase in selenium-dependent glutathione peroxidase (GPx) activity has been seen [40]. This probably contribute to HERV transcriptional reactivation by hindering the binding of methyl groups transferred by DNA methyltransferases and enhancing gene expression following inhibition of histone deacetylases and consequently promote disease conditions [37].

The hypothesis that MAP may be involved in HERV-W transactivation is also supported by the presence of highly expressed CD68+ in granulomatous lesions of infected goats, indicating high lysosome counts and acid phosphatase activity [41], similarly, increased expression of CD68+ infiltrating macrophages has been reported in the pancreas of T1D patients, in this case linked to HERV-W expression [22].

As humans are not the main target of MAP, it may act indirectly on immune homeostasis as a consequence of survival mechanisms that elude host defense against pathogens and conditions that favor the expression of HERV-W antigens. In conclusion, we have demonstrated high seropositivity against MAP and HERV-W peptides with a significant prevalence at disease onset and at the same time the moderate and high correlations present between the two agents; further investigation would help to elucidate the role of MAP as a plausible trigger for the expression of HERV-W antigens which in turn lead to immune
imbalance and subsequent disease onset. Additional follow up studies of Ab-titers over longer time frames are necessary to determine the role of both pathogens in T1D.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/pathogens10091135/s1, Table S1: Clinical Data T1D (n = 71).

**Author Contributions:** L.A.S. supervised, designed and conceived the study, L.A.S. and M.N. designed the experiment and analyzed the data statistically; M.N. drafted the manuscript and carried out the experiments; G.M., M.P. D.C. and P.M. recruited the T1D patients and healthy controls, analyzed the data, discussed the results and approved the manuscript. L.A.S. approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the UNISS fondi ricerca to L.A.S.

**Institutional Review Board Statement:** Study was approved by the Ethical Committee ASL 1 Sassari Prot 2149/CE/2.

**Informed Consent Statement:** Informed consent was obtained from all subject involved in the study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Taplin, C.; Barker, J. Autoantibodies in Type 1 Diabetes. *Autoimmunity* 2008, 41, 11–18. [CrossRef]
2. Islam, S.T.; Srinivasan, S.; Craig, M.E. Environmental Determinants of Type 1 Diabetes: A Role for Overweight and Insulin Resistance. *J. Paediatr. Child Health* 2014, 50, 874–879. [CrossRef] [PubMed]
3. Noble, J.A.; Valdes, A.M. Genetics of the HLA Region in the Prediction of Type 1 Diabetes. *Curr. Diabetes Rep.* 2011, 11, 533–542. [CrossRef] [PubMed]
4. Nyaga, D.M.; Vickers, M.H.; Jefferies, C.; Perry, J.K.; O’Sullivan, J.M. Type 1 Diabetes Mellitus-Associated Genetic Variants Contribute to Overlapping Immune Regulatory Networks. *Front. Genet.* 2018, 9, 1–11. [CrossRef] [PubMed]
5. Redondo, M.J.; Fain, P.R.; Eisenbarth, G.S. Genetics of Type 1A Diabetes. *Recent Prog. Horm. Res.* 2001, 56, 69–89. [CrossRef]
6. Craig, M.E.; Hattersley, A.; Donaghue, K.C. Definition, Epidemiology and Classification of Diabetes in Children and Adolescents. *Pediatric Diabetes* 2009, 10, 3–12. [CrossRef] [PubMed]
7. Esposito, S.; Toni, G.; Tascini, G.; Santi, E.; Berioli, M.G.; Principi, N. Environmental Factors Associated with Type 1 Diabetes. *Front. Endocrinol.* 2019, 10, 1–12. [CrossRef]
8. Knip, M.; Veijola, R.; Virtanen, S.M.; Hyytö, H.; Vaarala, O.; Äkerblom, H.K. Environmental Triggers and Determinants of Type 1 Diabetes. *Diabetes* 2005, 54, S125–S136. [CrossRef] [PubMed]
9. Cusick, M.F.; Libbey, J.E.; Fujinami, R.S. Molecular Mimicry as a Mechanism of Autoimmune Disease. *Clin. Rev. Allergy Immunol.* 2012, 42, 102–111. [CrossRef] [PubMed]
10. Sechi, L.A.; Paccagnini, D.; Salza, S.; Pacifico, A.; Ahmed, N.; Zanetti, S. Mycobacterium Avium Subspecies Paratuberculosis Bacteremia in Type 1 Diabetes Mellitus: An Infectious Trigger? *Clin. Infect. Dis.* 2008, 46, 148–149. [CrossRef]
11. Manca Bitti, M.L.; Masala, S.; Capasso, F.; Rapini, N.; Piccinini, S.; Angelini, F.; Pierantozzi, A.; Lidano, R.; Pietroatsi, S.; Paccagnini, D.; et al. Mycobacterium Avium Subsp. Paratuberculosis in an Italian Cohort of Type 1 Diabetes Pediatric Patients. *Clin. Dev. Immunol.* 2012, 2012, 1–6. [CrossRef]
12. Harris, N.B.; Barletta, R.G. Mycobacterium Avium Subsp. Paratuberculosis in Veterinary Medicine. *Clin. Microbiol. Rev.* 2001, 14, 489–512. [CrossRef]
13. Ellingson, J.L.E.; Anderson, J.L.; Koziczkowski, J.J.; Radcliff, R.P.; Sloan, S.J.; Allen, S.E.; Sullivan, N.M. Detection of Viable Mycobacterium Avium Subsp. Paratuberculosis in Retail Pasteurized Whole Milk by Two Culture Methods and PCR. *J. Food Prot.* 2005, 68, 966–972. [CrossRef] [PubMed]
14. Waddell, L.; Rajic, A.; Stark, K.; McEwen, S.A. Mycobacterium Avium Subsp. Paratuberculosis Detection in Animals, Food, Water and Other Sources or Vehicles of Human Exposure: A Scoping Review of the Existing Evidence. *Prev. Vet. Med.* 2016, 132, 32–48. [CrossRef]
15. Pierce, E.S. Possible Transmission of Mycobacterium Avium Subspecies Paratuberculosis through Potable Water: Lessons from an Urban Cluster of Crohn’s Disease. *Gut Pathog.* 2009, 1, 17. [CrossRef]
16. Bannantine, J.P.; Bermudez, L.E. No Holes Barred: Invasion of the Intestinal Mucosa by Mycobacterium Avium Subsp. Paratuberculosis. *Infect. Immun.* 2013, 81, 3960–3965. [CrossRef]
17. Rani, P.; Sechi, L.; Ahmed, N. Mycobacterium Avium Subsp. Paratuberculosis as a Trigger of Type-1 Diabetes: Destination Sardinia, or Beyond? *Gut Pathog.* 2010, 2, 1–6. [CrossRef] [PubMed]
18. Gröger, V.; Cynis, H. Human Endogenous Retroviruses and Their Putative Role in the Development of Autoimmune Disorders Such as Multiple Sclerosis. *Front. Microbiol.* 2018, 9, 265. [CrossRef]
19. Hansen, D.T.; Petersen, T.; Christensen, T. Retroviral Envelope Proteins: Involvement in Neuropathogenesis. *J. Neurol. Sci.* 2017, 380, 151–163. [CrossRef] [PubMed]
20. Lavillette, D.; Marin, M.; Ruggieri, A.; Mallet, F.; Cosset, F.-L.; Kabat, D. The Envelope Glycoprotein of Human Endogenous Retrovirus Type W Uses a Divergent Family of Amino Acid Transporters/Cell Surface Receptors. *J. Virol.* 2002, 76, 6442–6452. [CrossRef]

21. Hughes, J.F.; Coffin, J.M. A Novel Endogenous Retrovirus-Related Element in the Human Genome Resembles a DNA Transposon: Evidence for an Evolutionary Link? *Genomics* 2002, 80, 453–455. [CrossRef]

22. Levet, S.; Medina, J.; Joanou, J.; Demolder, A.; Queruel, N.; Réant, K.; Normand, M.; Seffals, M.; Dimier, J.; Germi, R.; et al. An Ancestral Retroviral Protein Identified as a Therapeutic Target in Type-1 Diabetes. *JCI Insight* 2017, 2, e94387. [CrossRef]

23. Bashratyan, R.; Regn, D.; Rahman, M.J.; Marquardt, K.; Fink, E.; Hu, W.Y.; Elder, J.H.; Binley, J.; Sherman, L.A.; Dai, Y.D. Type 1 Diabetes Pathogenesis Is Modulated by Spontaneous Autoimmune Responses to Endogenous Retrovirus Antigens in NOD Mice. *Eur. J. Immunol.* 2017, 47, 575–584. [CrossRef]

24. Curtin, P.; Bernard, C.; Levet, S.; Perron, H.; Porchet, H.; Médina, J.; Malpass, S.; Lloyd, D.; Simpson, R. A New Therapeutic Approach for Type 1 Diabetes: Rationale for GNbAC1, an Anti-HERV-W-Env Monoclonal Antibody. *Diabetes Obes. Metab.* 2018, 20, 2075–2084. [CrossRef]

25. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2011, 34, S62–S69. [CrossRef] [PubMed]

26. Asuero, A.G.; Sayago, A.; González, A.G. The Correlation Coefficient: An Overview. *Crit. Rev. Anal. Chem.* 2006, 36, 41–59. [CrossRef]

27. Norris, J.M.; Johnson, R.K.; Stene, L.C. Type 1 Diabetes—Early Life Origins and Changing Epidemiology. *Diabetes Obes. Metab.* 2010, 8, 226–238. [CrossRef]

28. Niegowska, M.; Wojda-Cuslag, M.; Stepien-Ptak, G.; Trojanek, J.; Michalkiewicz, J.; Szalecki, M.; Sechi, L.A. Anti-HERV-W Env Antibodies Are Correlated with Seroreactivity against Mycobacterium Avium Subsp. Paratuberculosis in Children and Youths at T1D Risk. *Sci. Rep.* 2019, 9, 1–8. [CrossRef]

29. Arru, G.; Caggiu, E.; Leoní, S.; Mameli, G.; Pugliatti, M.; Sechi, G.P.; Sechi, L.A. Natalizumab Modulates the Humoral Response against HERV-Wenv73-88 in a Follow-up Study of Multiple Sclerosis Patients. *J. Neurol. Sci.* 2015, 357, 106–108. [CrossRef] [PubMed]

30. Torrado, E.; Cooper, A.M. IL-17 and Th17 Cells in Tuberculosis. *Cytokine Growth Factor Rev.* 2010, 21, 455–462. [CrossRef]

31. Stephen-Victor, E.; Fickenscher, H.; Bayry, J. IL-26: An Emerging Proinflammatory Member of the IL-10 Cytokine Family with Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses. *PLoS Pathog.* 2016, 12, 4–9. [CrossRef]

32. Umemura, M.; Umemura, M.; Hajdú, C.; Stepień-Ptak, G.; Trojane, J.; Michalkiewicz, J.; Szalecki, M.; Sechi, L.A. Anti-HERV-W Env Antibodies Are Correlated with Seroreactivity against Mycobacterium Avium Subsp. Paratuberculosis in Children and Youths at T1D Risk. *Sci. Rep.* 2019, 9, 1–8. [CrossRef]

33. Stephen-Victor, E.; Fickenscher, H.; Bayry, J. IL-26: An Emerging Proinflammatory Member of the IL-10 Cytokine Family with Multifaceted Actions in Antiviral, Antimicrobial, and Autoimmune Responses. *PLoS Pathog.* 2016, 12, 4–9. [CrossRef]

34. Park, H.E.; Park, H.T.; Jung, Y.H.; Yoo, H.S. Gene Expression Profiles of Immune-Regulatory Genes in Whole Blood of Cattle with Bovine Tuberculosis. *Acta Diabetol.* Italy. 2014, 51, 577–585. [CrossRef]

35. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase. *PLoS ONE* 2015, 13, e0196502. [CrossRef] [PubMed]

36. Niegowska, M.; Rapini, N.; Piccinini, S.; Mameli, G.; Caggiu, E.; Bitti, M.L.M.; Sechi, L.A. Type 1 Diabetes At-Risk Children Highly Recognize Mycobacterium Avium Subspecies Paratuberculosis Epitopes Homologous to Human Znt8 and Proinsulin. *PLoS Pathog.* 2019, 15, e1007711. [CrossRef] [PubMed]

37. Morris, G.; Maes, M.; Murdjeva, S.; Rapini, N.; Bitti, M.L.M.; Sechi, L.A. Type 1 Diabetes At-Risk Children Highly Recognize Mycobacterium Avium Subspecies Paratuberculosis Epitopes Homologous to Human Znt8 and Proinsulin. *Crit. Rev. Anal. Chem.* 2016, 46, 242–248. [CrossRef] [PubMed]

38. Niegowska, M.; Rapini, N.; Piccinini, S.; Mameli, G.; Caggiu, E.; Bitti, M.L.M.; Sechi, L.A. Type 1 Diabetes At-Risk Children Highly Recognize Mycobacterium Avium Subspecies Paratuberculosis Epitopes Homologous to Human Znt8 and Proinsulin. *PLoS Pathog.* 2019, 15, e1007711. [CrossRef] [PubMed]

39. Morris, G.; Maes, M.; Murdjeva, S.; Rapini, N.; Bitti, M.L.M.; Sechi, L.A. Type 1 Diabetes At-Risk Children Highly Recognize Mycobacterium Avium Subspecies Paratuberculosis Epitopes Homologous to Human Znt8 and Proinsulin. *Crit. Rev. Anal. Chem.* 2016, 46, 242–248. [CrossRef] [PubMed]

40. Niegowska, M.; Rapini, N.; Piccinini, S.; Mameli, G.; Caggiu, E.; Bitti, M.L.M.; Sechi, L.A. Type 1 Diabetes At-Risk Children Highly Recognize Mycobacterium Avium Subspecies Paratuberculosis Epitopes Homologous to Human Znt8 and Proinsulin. *Crit. Rev. Anal. Chem.* 2016, 46, 242–248. [CrossRef] [PubMed]

41. Qasem, A.; Abdel-Aty, A.; Abu-Suwa, H.; Naser, S.A. Oxidative Stress Due to Mycobacterium Avium Subspecies Paratuberculosis (MAP) Infection Upregulates Selenium-Dependent GPx Activity. *Gut Pathog.* 2016, 8, 1–9. [CrossRef]

42. Valheim, M.; Siguroardóttir, Ö.G.; Storsæter, A.K.; Aune, L.G.; Press, C.M.L. Characterization of Macrophages and Occurrence of Cells in Intestinal Lesions of Subclinical Paratuberculosis in Goats. *J. Comp. Pathol.* 2004, 131, 221–232. [CrossRef] [PubMed]